KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Cost of Revenue (2018 - 2025)

Ionis Pharmaceuticals (IONS) has 8 years of Cost of Revenue data on record, last reported at $8.0 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 107.75% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $15.9 million, up 41.84%, while the annual FY2025 figure was $15.9 million, 41.85% up from the prior year.
  • Cost of Revenue reached $8.0 million in Q4 2025 per IONS's latest filing, up from $2.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $8.0 million in Q4 2025 and bottomed at $1.1 million in Q3 2024.
  • Average Cost of Revenue over 5 years is $3.1 million, with a median of $2.8 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: plummeted 67.79% in 2023, then surged 118.3% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $2.2 million in 2021, then surged by 65.59% to $3.7 million in 2022, then decreased by 16.93% to $3.1 million in 2023, then increased by 25.08% to $3.8 million in 2024, then surged by 107.75% to $8.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $8.0 million in Q4 2025, $2.3 million in Q3 2025, and $4.2 million in Q2 2025.